Wedbush Securities Inc. grew its position in Sanofi SA (NYSE:SNY) by 8.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,888 shares of the company’s stock after purchasing an additional 1,221 shares during the quarter. Wedbush Securities Inc.’s holdings in Sanofi were worth $687,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SNY. Ibex Wealth Advisors purchased a new position in Sanofi in the second quarter worth $25,000. Bessemer Group Inc. grew its holdings in Sanofi by 292.4% in the second quarter. Bessemer Group Inc. now owns 671 shares of the company’s stock worth $29,000 after purchasing an additional 500 shares during the last quarter. Nkcfo LLC purchased a new position in Sanofi in the first quarter worth $35,000. Cullen Frost Bankers Inc. purchased a new stake in shares of Sanofi during the first quarter valued at $35,000. Finally, Howe & Rusling Inc. purchased a new stake in shares of Sanofi during the first quarter valued at $38,000. 7.04% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages have recently weighed in on SNY. TheStreet raised shares of Sanofi from a “c+” rating to a “b-” rating in a report on Friday, June 21st. UBS Group raised shares of Sanofi from a “neutral” rating to a “buy” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a report on Tuesday, August 6th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $51.00.

In other Sanofi news, major shareholder Sanofi bought 93,750 shares of the firm’s stock in a transaction that occurred on Monday, July 22nd. The stock was bought at an average cost of $16.00 per share, for a total transaction of $1,500,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.00% of the stock is owned by insiders.

Shares of SNY traded up $0.01 during trading hours on Thursday, reaching $41.75. 18,552 shares of the company traded hands, compared to its average volume of 1,242,809. The company has a market capitalization of $103.37 billion, a PE ratio of 13.35, a P/E/G ratio of 2.41 and a beta of 0.67. The company has a quick ratio of 0.85, a current ratio of 1.22 and a debt-to-equity ratio of 0.40. Sanofi SA has a 12-month low of $40.00 and a 12-month high of $45.62. The stock has a fifty day simple moving average of $42.25.

Sanofi (NYSE:SNY) last announced its quarterly earnings data on Monday, July 29th. The company reported $0.74 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.07. The firm had revenue of $8.63 billion for the quarter, compared to analyst estimates of $8.42 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The business’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.25 earnings per share. On average, analysts anticipate that Sanofi SA will post 3.1 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Read More: Price-Sales Ratio

Want to see what other hedge funds are holding SNY? Visit to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with's FREE daily email newsletter.